Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single and Multiple Oral Doses of BAY 2395840 Including the Relative Bioavailability Between Solution and Tablet Formulation and the Effect of Food on the Pharmacokinetics of BAY 2395840 in Healthy Men
Latest Information Update: 29 Aug 2022
At a glance
- Drugs BAY 2395840 (Primary) ; BAY 2395840 (Primary)
- Indications Endometriosis
- Focus Adverse reactions
- Sponsors Bayer
Most Recent Events
- 29 Aug 2022 New trial record